Elan Corp. plc shareholders have a lot to consider before a June 17 meeting to decide the fate of the biotech. Investors can walk away after pocketing the $6.4 billion proposed by suitor Royalty Pharma, or stick with Elan in the hopes that the company's new royalty-backed business model will ultimately provide a better return.

Elan kicked off last week announcing three deals on the same day, as well as a $200 million share buyback and a note deal that priced at $850 million three days later.